mhurhangee/ep-ind-claims huggingface dataset:
Method for segmentation of an organ structure of an examination object in medical image data, comprising the following method steps: - Acquisition of genetic data of the examination object, which characterises a morphological variation of the organ structure, - Acquisition of medical image data from the examination object, - Segmentation of the organ structure in the medical image data by means of a segmentation algorithm, wherein the genetic data is entered into the segmentation algorithm in addition to the medical image data as input parameters and wherein the segmentation algorithm takes account of the morphological variation of the organ structure during the segmentation of the organ structure, - Provision of the segmented organ structure, wherein the acquisition of the genetic data comprises a check as to whether a genetic variant, which leads to the morphological variation of the organ structure, is present in the genetic data of the examination object, wherein a first artificial neural network and a second artificial neural network are available for the segmentation of the organ structure, wherein the first artificial neural network has been trained by means of a first training collective, which has the genetic variant, and the second artificial neural network has been trained by means of a second training collective, which does not have the genetic variant, wherein in accordance with the result of the check, the first artificial neural network or the second artificial neural network will be used for the segmentation of the organ structure. - Acquisition of genetic data of the examination object, which characterises a morphological variation of the organ structure, - Acquisition of medical image data from the examination object, - Segmentation of the organ structure in the medical image data by means of a segmentation algorithm, wherein the genetic data is entered into the segmentation algorithm in addition to the medical image data as input parameters and wherein the segmentation algorithm takes account of the morphological variation of the organ structure during the segmentation of the organ structure, - Provision of the segmented organ structure,
A smartcard comprising: a card body enclosing a flexible circuit; a cavity formed in the card body; and a contact pad received in the cavity; characterised in that conductive extension members extend away from the flexible circuit, wherein a material forming the extension members has a melting temperature higher than the melting temperature of a material forming the card body, and wherein the extension members have a height of at least 200μm; the cavity exposes the extension members; and the contact pad is connected to the extension members by an electrical connection, wherein the electrical connection was formed at a temperature below the melting temperature of the material forming the card body. a card body enclosing a flexible circuit; a cavity formed in the card body; and a contact pad received in the cavity; characterised in that conductive extension members extend away from the flexible circuit, wherein a material forming the extension members has a melting temperature higher than the melting temperature of a material forming the card body, and wherein the extension members have a height of at least 200μm; the cavity exposes the extension members; and the contact pad is connected to the extension members by an electrical connection, wherein the electrical connection was formed at a temperature below the melting temperature of the material forming the card body.
An immunoanalytical method of diagnosing, or supporting the diagnosis of, stroke in a subject comprising measuring the amount of a GFAP derivative comprising the sequence ETRASERAEMME present in a sample which has been taken from the subject, the method incorporating an antibody which binds to an epitope of the GFAP derivative within the sequence ETRASERAEMME, wherein an amount of GFAP derivative in the sample bound by the antibody which is greater than the amount of the GFAP in a control subject is indicative of stroke.
A method for transmitting, by a user equipment, UE, a report message in a wireless communication system, the method comprising: receiving, by the UE, a configuration of immediate minimization of drive tests, MDT, indicating a multicast traffic channel, MTCH, via system information or multicast control channel, MCCH, wherein the MTCH indicated by the configuration is used for determining whether or not the immediate MDT for a multimedia broadcast multicast service, MBMS, service is enabled by a first network, and wherein the first network is a network providing the MBMS service; receiving, by the UE, the MBMS service from the MTCH indicated by the configuration; if the MBMS service is received from the MTCH indicated by the configuration, determining that the immediate MDT for the MBMS service is enabled by the first network; detecting, by the UE, a problem for reception of the MBMS service; and upon detecting the problem, immediately transmitting, by the UE, a report message. receiving, by the UE, a configuration of immediate minimization of drive tests, MDT, indicating a multicast traffic channel, MTCH, via system information or multicast control channel, MCCH, wherein the MTCH indicated by the configuration is used for determining whether or not the immediate MDT for a multimedia broadcast multicast service, MBMS, service is enabled by a first network, and wherein the first network is a network providing the MBMS service; receiving, by the UE, the MBMS service from the MTCH indicated by the configuration; if the MBMS service is received from the MTCH indicated by the configuration, determining that the immediate MDT for the MBMS service is enabled by the first network; detecting, by the UE, a problem for reception of the MBMS service; and upon detecting the problem, immediately transmitting, by the UE, a report message.
A drug delivery system for administration of at least one pharmaceutically active substance that is a cationic amphiphile by itself and at least one other pharmaceutically active substance having a solubility per se in water of less than 100 μg/ml, which pharmaceutically active substances are present in the drug delivery system in particles of a complex between said pharmaceutically active substances and a sodium salt of the methyl ester of N-all-trans-retinoyl cysteic acid, a sodium salt of methyl ester of N-13-cis-retinoyl cysteic acid, or a combination thereof, said particles of said complex having an effective average particle size of less than 100 nm, wherein - the particles of said complex are essentially amorphous; - the particles of said complex are entrapped in nanoparticles formed of a sodium salt of the methyl ester of N-all-trans-retinoyl cysteic acid, sodium salt of methyl ester of N-13-cis-retinoyl cysteic acid, or a combination thereof; and - the weight-to-weight ratio of said sodium salt of methyl ester of N-all-trans-retinoyl cysteic acid, sodium salt of methyl ester of N-13-cis-retinoyl cysteic acid, or combination thereof, to the weight of said complex is in the range from 0.5:1 to 20:1. - the particles of said complex are essentially amorphous; - the particles of said complex are entrapped in nanoparticles formed of a sodium salt of the methyl ester of N-all-trans-retinoyl cysteic acid, sodium salt of methyl ester of N-13-cis-retinoyl cysteic acid, or a combination thereof; and - the weight-to-weight ratio of said sodium salt of methyl ester of N-all-trans-retinoyl cysteic acid, sodium salt of methyl ester of N-13-cis-retinoyl cysteic acid, or combination thereof, to the weight of said complex is in the range from 0.5:1 to 20:1.
Method for the spatial filtering of acoustic waves, which are radiated or transmitted by one or more sources and propagate in water, and which are received by a receiving arrangement with a plurality of electroacoustic and/or optoacoustic transducers for forming received signals, characterised by that the method has the following steps: - formation of a spatial energy spectrum from the received signals over all control directions to be considered, - selection of significant levels (p(i)) from the energy spectrum for each control direction (i) to be considered, - determination of a signal model matrix from an antenna response (a(k)) related to the receiving arrangement and the selected levels (p), - determination of a source control vector (aSource(k)) from the antenna response (a(k)) and the signal model matrix, - checking by means of a filter control vector module for each control direction (i) to be considered whether a source exists in this control direction (i), - determination of a filter control vector (aFilter(k)), wherein for the case that no source exists in the control direction (i) to be considered, the filter control vector (aFilter(k)) corresponds to the previously determined source control vector (aSource(k)) or for the case that a source exists in the control direction (i) to be considered, the filter control vector (aFilter(k)) is determined from the signal model matrix, the antenna response (a(k)) and the selected level p(i) for this control direction (i) and - determination of an optimised filter vector taking account of the filter control vector (aFilter(k)) for executing the spatial filtering of the acoustic waves radiated or transmitted by a source. - formation of a spatial energy spectrum from the received signals over all control directions to be considered, - selection of significant levels (p(i)) from the energy spectrum for each control direction (i) to be considered, - determination of a signal model matrix from an antenna response (a(k)) related to the receiving arrangement and the selected levels (p), - determination of a source control vector (aSource(k)) from the antenna response (a(k)) and the signal model matrix, - checking by means of a filter control vector module for each control direction (i) to be considered whether a source exists in this control direction (i), - determination of a filter control vector (aFilter(k)), wherein for the case that no source exists in the control direction (i) to be considered, the filter control vector (aFilter(k)) corresponds to the previously determined source control vector (aSource(k)) or for the case that a source exists in the control direction (i) to be considered, the filter control vector (aFilter(k)) is determined from the signal model matrix, the antenna response (a(k)) and the selected level p(i) for this control direction (i) and - determination of an optimised filter vector taking account of the filter control vector (aFilter(k)) for executing the spatial filtering of the acoustic waves radiated or transmitted by a source.
A Y-shaped surgical implant comprising: a base comprising a fixed length of implant material between a distal base end and a proximal base end, a sacral leaf, a first vaginal leaf, and a width, a moveable junction that is moveable along the length between the distal base end and the proximal base end, the moveable junction including a connector in the form of a slider securely attached to a distal end of the second vaginal leaf, the slider being moveably attached to the base along a width of the base in a manner that allows the slider to maintain engagement with the base while moving along the length of the base; wherein the first vaginal leaf extends between the proximal base end and the moveable junction, the sacral leaf extends between the moveable junction and the distal base end, and a second vaginal leaf comprising implant material extends from the moveable junction. a base comprising a fixed length of implant material between a distal base end and a proximal base end, a sacral leaf, a first vaginal leaf, and a width, a moveable junction that is moveable along the length between the distal base end and the proximal base end, the moveable junction including a connector in the form of a slider securely attached to a distal end of the second vaginal leaf, the slider being moveably attached to the base along a width of the base in a manner that allows the slider to maintain engagement with the base while moving along the length of the base; wherein the first vaginal leaf extends between the proximal base end and the moveable junction, the sacral leaf extends between the moveable junction and the distal base end, and a second vaginal leaf comprising implant material extends from the moveable junction.
A loading basket for use with a stent delivery system, the basket having a proximal end, a distal end, and a surface, the basket comprising a proximal end portion at the proximal end, the proximal end portion having a diameter; a proximal body portion connected to the proximal end portion, the proximal body portion having a diameter; a distal transition portion connected to the proximal body portion, a distal body portion connected to the distal transition portion, the distal body portion having a diameter; and a distal end portion connected to the distal body portion and forming the distal end of the basket, wherein the distal end portion has a diameter that tapers from a diameter of the distal body portion to a diameter at the distal end of the basket, characterized in that the diameter at the distal end is less than the diameter of the distal body portion, the diameter at the distal end is greater than the diameter of the proximal end portion, the diameter of the proximal body portion is greater than the diameter of the distal body portion, and the diameter of the distal body portion is greater than the diameter of the proximal end portion.
A compound of Formula: or a physiologically acceptable salt thereof; R 1 and R 2 are independently H, C 1-6 alkyl or halo-substituted C 1-6 alkyl; R 3 is halo, C 1-6 alkyl, or a halo-substituted C 1-6 alkyl; R 4 is H; alternatively, R 3 and R 4 together with the carbon atoms to which they are attached to may form a 5-6 membered ring containing 1-3 heteroatoms selected from N, O and S, and optionally substituted with 1-2 R 10 groups wherein R 10 is halo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, optionally substituted phenyl or NR 2; R 5 and R 6 are independently C 1-6 alkyl, C 1-6 alkoxy, C 2-6 alkenyl or C 2-6 alkynyl, each of which may be optionally substituted with halo, amino or hydroxyl groups; halo, nitro, cyano, CR(OR 17)R 17, OR 17, NR(R 17), CR(R 17)NRR 17, (CR 2) q Y, C O 0-1 R 17, C NR(R 17), C CRR 17 -NR(R 17), C NR(CR 2) p NR(R 17), C NR(CR 2) p OR 17, C NR(CR 2) p SR 17, C NR(CR 2) p S 1-2 R 18, S 0-2 R 18, (CR 2) 1-6 NR(CR 2) p OR 17, (CR 2) 1-6 NR(CR 2) q C R 18, S 2 NRR 17, S 2 NR(CR 2) p NR(R 17), or S 2 NR(CR 2) p OR 17; R 7 is S 0-2 R 19, S 2 NRR 20 or C NR(R 20); wherein R 19 and R 20 are independently C 1-6 alkyl, halo-substituted C 1-6 alkyl or C 3-7 cycloalkyl; or R 20 is H; each R 9 is independently -L-CR(OR 17)-C t F (2t+1) wherein t is 1-3; -L-C -CR(R 17)-NRR 17, -L-C -NR-(CR 2) p -NRR 17, -L-C NR(CR 2) p OR 17,,-L-C -(CR 2) q -NR-C -R 18, -L-C NR(CR 2) p SR 17, -L-C NR(CR 2) p S 1-2 R 18, (CR 2) p NR(CR 2) p OR 17 or (CR 2) p NR-L-C R 18, -L-S 2 R 18, -L-S 2 NRR 17, -L-S 2 NR(CR 2) p NR(R 17), -L-S 2 NR(CR 2) p OR 17 or a radical selected from formula (a), (b), (c) or (d): wherein R 11, R 12, R 13, R 14, R 15 and R 16 are independently selected from H, or C 1-6 alkyl, C 1-6 alkoxy, C 2-6 alkenyl or C 2-6 alkynyl, each of which may be optionally substituted with halo, amino or hydroxyl groups; or R 11 and R 12, R 12 and R 15, R 15 and R 16, R 13 and R 14, or R 13 and R 15 together with the carbon and/or nitrogen atoms to which they are attached may form a 3-7 membered saturated, unsaturated or partially unsaturated ring optionally containing up to 3 atoms or groups selected from C, N, O and S 0-2; L is (CR 2) 1-4 or a bond; R 17 and R 18 are independently C 1-6 alkyl, halo-substituted C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl; or R 17 is H; Y is a C 3-12 carbocyclic ring, C 6-10 aryl; or a 5-10 membered heteroaryl or 4-10 membered heterocyclic ring; each of which is optionally substituted with 1-3 R 6 groups; each R is H or C 1-6 alkyl; p is 2-4; and q is 0-4.
Method for verifying a security document using a freely programmable mobile phone, wherein the security document includes at least one pigment-like fluorescent print element as a security feature, which element is mounted in a test area and is excitable in a first wavelength range of electromagnetic radiation to emit electromagnetic radiation in a second wavelength range, wherein the first and second wavelength ranges are both in the visible spectral range, and wherein the pigment-like fluorescent print element is formed by a nitride fluorescent material with a host lattice which has a structure M-Si-N, M-Si-O-N, M-Al-N, M-Si-Al-N or M-Si-Al-O-N and is doped with Eu 2+ as activator, or with a host lattice which has a structure M-Si-N, La-Si-N, M-Si-Al-N or M-Si-Al-O-N and is doped with Ce 3+ as activator, wherein M stands for a metal, comprising the following steps: - exciting the fluorescent print element by means of a light source emitting in the first wavelength range; - detecting the emission of the fluorescent printing element with a photosensor; - evaluating the emission of the fluorescent printing element detected in the second emission wavelength range by comparison with predetermined data; - outputting the result of verification depending on the result of the comparison performed. - exciting the fluorescent print element by means of a light source emitting in the first wavelength range; - detecting the emission of the fluorescent printing element with a photosensor; - evaluating the emission of the fluorescent printing element detected in the second emission wavelength range by comparison with predetermined data; - outputting the result of verification depending on the result of the comparison performed.
A method for promoting coloring of a fruit, the method comprising: applying one or more kinds of amino acids selected from leucine and isoleucine, and abscisic acid to a fruit plant.
An aqueous composition comprising torasemide, a buffer or an alkalizing agent and at least one organic solvent selected from the group comprising alcohols derived from propane, preferably selected from propylene glycol, glycerol, propane-1,3-diol, propanol, isopropanol and mixtures thereof, characterized in that the concentration of organic solvent by weight is greater than or equal to 30% relative to the total weight of the composition, preferably greater than or equal to 35% and even more preferably greater than or equal to 40%.
A conjugate comprising: (a) an isolated or a synthetic targeting peptide comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 8; and (b) a component, to which the targeting peptide is conjugated, the component being selected from the group consisting of polymeric micelles, lipoprotein-based drug carriers, nanoparticle drug carriers, a chemotherapeutic agent, a micelle, a liposome, dendrimers, a polymer, a lipid, an oligonucleotide, a peptide, a polypeptide, a protein, a prostate cancer cell, a stem cell, and an imaging agent. (a) an isolated or a synthetic targeting peptide comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 8; and (b) a component, to which the targeting peptide is conjugated, the component being selected from the group consisting of polymeric micelles, lipoprotein-based drug carriers, nanoparticle drug carriers, a chemotherapeutic agent, a micelle, a liposome, dendrimers, a polymer, a lipid, an oligonucleotide, a peptide, a polypeptide, a protein, a prostate cancer cell, a stem cell, and an imaging agent.
Exhaust channel for a vacuum cleaner or a robotic vacuum cleaner, having a first opening or cut-out for the entry of waste air, a second opening or cut-out for discharging the waste air, and at least one wall, which connects the first opening or cut-out to the second opening or cut-out, wherein the exhaust channel routes waste air from the first opening or cut-out to the second opening or cut-out, characterised in that a third opening or cut-out for discharging the waste air cleaned by a provided dust separation unit is provided as an additional outlet opening, through which waste air flows into the interior of the vacuum cleaner or the robotic vacuum cleaner and/or the wall consists at least partially of an air-permeable material.
Blocking device for a damper drive, wherein the blocking device can be transferred by activation from an inactive state to an alternative, activated state, and the blocking device comprises: - a blocking element, wherein the blocking element is movably mounted and as a result can be moved between a release position, assumed in the inactive state, and a blocking position, assumed in the active state, and wherein the blocking element permits a movement of an output member of the damper drive when in the release position and, in the blocking position, blocks the output member in a safety position; - a drive element, wherein the drive element is configured in such a way that it moves the blocking element from the release position to the blocking position when the blocking device is activated; - an activation element, wherein the activation element is operatively connected to the blocking element and the drive element; and wherein, when a blocking temperature is exceeded, the blocking device is activated by means of an irreversible shape change of the activation element. - a blocking element, wherein the blocking element is movably mounted and as a result can be moved between a release position, assumed in the inactive state, and a blocking position, assumed in the active state, and wherein the blocking element permits a movement of an output member of the damper drive when in the release position and, in the blocking position, blocks the output member in a safety position; - a drive element, wherein the drive element is configured in such a way that it moves the blocking element from the release position to the blocking position when the blocking device is activated; - an activation element, wherein the activation element is operatively connected to the blocking element and the drive element; and wherein, when a blocking temperature is exceeded, the blocking device is activated by means of an irreversible shape change of the activation element.
A method for forming a light emitting diode, comprising: providing a semiconductor substrate, wherein the semiconductor substrate is an n-doped silicon substrate; forming a first bonding layer on the semiconductor substrate, wherein the first bonding layer comprises palladium; providing a sapphire substrate; forming a sacrificial layer, a light emitting diode die, a contact electrode layer and a second bonding layer successively on the sapphire substrate, and the light emitting diode die comprising a cap layer, an active layer and a second buffer layer which are formed successively on the sacrificial layer, the cap layer comprising p-doped gallium nitride, the second buffer layer comprising n-doped gallium nitride, the contact electrode layer comprising titanium, and the second bonding layer comprising palladium, silver or indium; bonding the first bonding layer and the second bonding layer; and removing the sacrificial layer and peeling the sapphire substrate. providing a semiconductor substrate, wherein the semiconductor substrate is an n-doped silicon substrate; forming a first bonding layer on the semiconductor substrate, wherein the first bonding layer comprises palladium; providing a sapphire substrate; forming a sacrificial layer, a light emitting diode die, a contact electrode layer and a second bonding layer successively on the sapphire substrate, and the light emitting diode die comprising a cap layer, an active layer and a second buffer layer which are formed successively on the sacrificial layer, the cap layer comprising p-doped gallium nitride, the second buffer layer comprising n-doped gallium nitride, the contact electrode layer comprising titanium, and the second bonding layer comprising palladium, silver or indium; bonding the first bonding layer and the second bonding layer; and removing the sacrificial layer and peeling the sapphire substrate.